慢性阻塞性肺病患病率與死亡率高，得到越來(lái)越多的藥物研發(fā)人員的關(guān)注。由于傳統(tǒng)藥物的不良反應(yīng)與局限性，新型藥物的研發(fā)至關(guān)重要?，F(xiàn)階段研發(fā)的熱點(diǎn)主要為新型抗膽堿藥物、新一代超長(zhǎng)效支氣管擴(kuò)張劑、新型磷酸二酯酶-4抑制劑、內(nèi)皮素抑制劑、蛋白酶抑制劑等，其代表性藥物分別為格隆溴銨、茚達(dá)特羅、羅氟司特、bimosiamose、米地司坦等。對(duì)慢性阻塞性肺病的新型藥物的研發(fā)進(jìn)展與前景進(jìn)行綜述。

Given the high morbidity and mortality of chronic obstructive pulmonary disease (COPD), more drug developers get attention to it. Due to the adverse reaction and limitation of traditional medicines, the study and development of the new drug are very important. At present, hot spots in the research of main stage are new anticholinergic drugs, new generation of ultra-long-acting bronchodilators, new phosphodiesterase-4 (PDE-4) inhibitors, endothelin inhibitors, and protease inhibitors etc. The representative drugs are glycopyrrolate bromide, indacaterol, roflumilast, bimosiamose, midesteine, respectively. In this paper, the development and prospect of the new drug on COPD have been reviewed.